Proscillaridin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Proscillaridin
Accession Number
DB13307
Type
Small Molecule
Groups
Experimental
Description

Proscillaridin is a cardiac glycoside that is derived from plants of the genus Scilla and in Drimia maritima (Scilla maritima). Studies suggest the potential cytotoxic and anticancer property of proscillaridin, based on evidence of the drug potently disrupting topoisomerase I and II activity at nanomolar drug concentrations [1] and triggering cell death and blocking cell proliferation of glioblastoma cell lines [2].

Structure
Thumb
Synonyms
Not Available
External IDs
A-32686
Categories
UNII
KC6BL281EN
CAS number
466-06-8
Weight
Average: 530.658
Monoisotopic: 530.287968312
Chemical Formula
C30H42O8
InChI Key
MYEJFUXQJGHEQK-ALRJYLEOSA-N
InChI
InChI=1S/C30H42O8/c1-16-24(32)25(33)26(34)27(37-16)38-19-8-11-28(2)18(14-19)5-6-22-21(28)9-12-29(3)20(10-13-30(22,29)35)17-4-7-23(31)36-15-17/h4,7,14-16,19-22,24-27,32-35H,5-6,8-13H2,1-3H3/t16-,19-,20+,21-,22+,24-,25+,26+,27-,28-,29+,30-/m0/s1
IUPAC Name
5-[(1S,2R,5S,10R,11S,14S,15R)-11-hydroxy-2,15-dimethyl-5-{[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl]-2H-pyran-2-one
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
10-hydroxycamptothecinProscillaridin may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Investigational
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideProscillaridin may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-chloroethyl-3-sarcosinamide-1-nitrosoureaProscillaridin may decrease the cardiotoxic activities of 2-chloroethyl-3-sarcosinamide-1-nitrosourea.Investigational
2-MethoxyestradiolProscillaridin may decrease the cardiotoxic activities of 2-Methoxyestradiol.Investigational
3-MethoxybenzamideProscillaridin may decrease the cardiotoxic activities of 3-Methoxybenzamide.Experimental
3,3'-diindolylmethaneProscillaridin may decrease the cardiotoxic activities of 3,3'-diindolylmethane.Investigational
3,4-Dihydroxybenzoic AcidProscillaridin may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.Experimental
6-O-benzylguanineProscillaridin may decrease the cardiotoxic activities of 6-O-benzylguanine.Investigational
7-HydroxystaurosporineProscillaridin may decrease the cardiotoxic activities of 7-Hydroxystaurosporine.Experimental, Investigational
8-azaguanineProscillaridin may decrease the cardiotoxic activities of 8-azaguanine.Experimental
9-aminocamptothecinProscillaridin may decrease the cardiotoxic activities of 9-aminocamptothecin.Investigational
AbirateroneProscillaridin may decrease the cardiotoxic activities of Abiraterone.Approved
AcebutololAcebutolol may increase the bradycardic activities of Proscillaridin.Approved
AclarubicinProscillaridin may decrease the cardiotoxic activities of Aclarubicin.Investigational
Acridine CarboxamideProscillaridin may decrease the cardiotoxic activities of Acridine Carboxamide.Investigational
ActeosideProscillaridin may decrease the cardiotoxic activities of Acteoside.Investigational
AfatinibProscillaridin may decrease the cardiotoxic activities of Afatinib.Approved
AfimoxifeneProscillaridin may decrease the cardiotoxic activities of Afimoxifene.Investigational
AfliberceptProscillaridin may decrease the cardiotoxic activities of Aflibercept.Approved
AlanosineProscillaridin may decrease the cardiotoxic activities of L-alanosine.Investigational
AlatrofloxacinProscillaridin may decrease the cardiotoxic activities of Alatrofloxacin.Withdrawn
AlbendazoleProscillaridin may decrease the cardiotoxic activities of Albendazole.Approved, Vet Approved
AlcuroniumAlcuronium may increase the arrhythmogenic activities of Proscillaridin.Experimental
AldesleukinProscillaridin may decrease the cardiotoxic activities of Aldesleukin.Approved
AlectinibProscillaridin may decrease the cardiotoxic activities of Alectinib.Approved
AlemtuzumabProscillaridin may decrease the cardiotoxic activities of Alemtuzumab.Approved, Investigational
AlitretinoinProscillaridin may decrease the cardiotoxic activities of Alitretinoin.Approved, Investigational
AlprenololAlprenolol may increase the bradycardic activities of Proscillaridin.Approved, Withdrawn
AltretamineProscillaridin may decrease the cardiotoxic activities of Altretamine.Approved
AlvocidibProscillaridin may decrease the cardiotoxic activities of Alvocidib.Experimental, Investigational
AmikacinThe serum concentration of Proscillaridin can be decreased when it is combined with Amikacin.Approved, Vet Approved
AmilorideThe therapeutic efficacy of Proscillaridin can be decreased when used in combination with Amiloride.Approved
AminoglutethimideProscillaridin may decrease the cardiotoxic activities of Aminoglutethimide.Approved, Investigational
Aminolevulinic acidProscillaridin may decrease the cardiotoxic activities of Aminolevulinic acid.Approved
AmiodaroneThe serum concentration of Proscillaridin can be increased when it is combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Proscillaridin can be increased when it is combined with Amodiaquine.Approved, Investigational
AmonafideProscillaridin may decrease the cardiotoxic activities of Amonafide.Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Proscillaridin.Approved, Investigational
AmrubicinProscillaridin may decrease the cardiotoxic activities of Amrubicin.Approved, Investigational
AmsacrineProscillaridin may decrease the cardiotoxic activities of Amsacrine.Approved
AnagrelideProscillaridin may decrease the cardiotoxic activities of Anagrelide.Approved
AnastrozoleProscillaridin may decrease the cardiotoxic activities of Anastrozole.Approved, Investigational
AnecortaveProscillaridin may decrease the cardiotoxic activities of Anecortave.Investigational
annamycinProscillaridin may decrease the cardiotoxic activities of annamycin.Investigational
AP 12009Proscillaridin may decrease the cardiotoxic activities of AP 12009.Investigational
AP24534Proscillaridin may decrease the cardiotoxic activities of AP24534.Investigational
ApaziquoneProscillaridin may decrease the cardiotoxic activities of Apaziquone.Investigational
ApramycinThe serum concentration of Proscillaridin can be decreased when it is combined with Apramycin.Experimental, Vet Approved
ArbekacinThe serum concentration of Proscillaridin can be decreased when it is combined with Arbekacin.Approved, Investigational
Arotinoid acidProscillaridin may decrease the cardiotoxic activities of Arotinoid acid.Experimental
ArotinololArotinolol may increase the bradycardic activities of Proscillaridin.Approved, Investigational
Arsanilic acidProscillaridin may decrease the cardiotoxic activities of Arsanilic acid.Experimental, Vet Approved
Arsenic trioxideProscillaridin may decrease the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
AsparaginaseProscillaridin may decrease the cardiotoxic activities of Asparaginase.Approved
AtenololAtenolol may increase the bradycardic activities of Proscillaridin.Approved
AtezolizumabProscillaridin may decrease the cardiotoxic activities of Atezolizumab.Approved
AtracuriumAtracurium may increase the arrhythmogenic activities of Proscillaridin.Experimental, Investigational
Atracurium besylateAtracurium besylate may increase the arrhythmogenic activities of Proscillaridin.Approved
AxitinibProscillaridin may decrease the cardiotoxic activities of Axitinib.Approved, Investigational
AzacitidineProscillaridin may decrease the cardiotoxic activities of Azacitidine.Approved, Investigational
AzathioprineProscillaridin may decrease the cardiotoxic activities of Azathioprine.Approved
Azelaic AcidProscillaridin may decrease the cardiotoxic activities of Azelaic Acid.Approved
AzithromycinThe serum concentration of Proscillaridin can be increased when it is combined with Azithromycin.Approved
BalsalazideThe serum concentration of Proscillaridin can be decreased when it is combined with Balsalazide.Approved, Investigational
BatimastatProscillaridin may decrease the cardiotoxic activities of Batimastat.Experimental
BefunololBefunolol may increase the bradycardic activities of Proscillaridin.Experimental
BekanamycinThe serum concentration of Proscillaridin can be decreased when it is combined with Bekanamycin.Experimental
BelinostatProscillaridin may decrease the cardiotoxic activities of Belinostat.Approved, Investigational
BelotecanProscillaridin may decrease the cardiotoxic activities of Belotecan.Investigational
BendamustineProscillaridin may decrease the cardiotoxic activities of Bendamustine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Proscillaridin.Approved
BesifloxacinProscillaridin may decrease the cardiotoxic activities of Besifloxacin.Approved
BetaxololBetaxolol may increase the bradycardic activities of Proscillaridin.Approved
BevacizumabProscillaridin may decrease the cardiotoxic activities of Bevacizumab.Approved, Investigational
BevantololBevantolol may increase the bradycardic activities of Proscillaridin.Approved
BexaroteneProscillaridin may decrease the cardiotoxic activities of Bexarotene.Approved, Investigational
BicalutamideProscillaridin may decrease the cardiotoxic activities of Bicalutamide.Approved
BinetrakinProscillaridin may decrease the cardiotoxic activities of Binetrakin.Investigational
BisoprololBisoprolol may increase the bradycardic activities of Proscillaridin.Approved
BizelesinProscillaridin may decrease the cardiotoxic activities of Bizelesin.Investigational
BleomycinProscillaridin may decrease the cardiotoxic activities of Bleomycin.Approved
BlinatumomabProscillaridin may decrease the cardiotoxic activities of Blinatumomab.Approved
BopindololBopindolol may increase the bradycardic activities of Proscillaridin.Approved
BortezomibProscillaridin may decrease the cardiotoxic activities of Bortezomib.Approved, Investigational
BosutinibProscillaridin may decrease the cardiotoxic activities of Bosutinib.Approved
Brentuximab vedotinProscillaridin may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
BroxuridineProscillaridin may decrease the cardiotoxic activities of Broxuridine.Investigational
Bryostatin 1Proscillaridin may decrease the cardiotoxic activities of Bryostatin 1.Investigational
BSI-201Proscillaridin may decrease the cardiotoxic activities of BSI-201.Investigational
BucindololBucindolol may increase the bradycardic activities of Proscillaridin.Investigational
BufuralolBufuralol may increase the bradycardic activities of Proscillaridin.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Proscillaridin.Approved
BupranololBupranolol may increase the bradycardic activities of Proscillaridin.Approved
BuserelinProscillaridin may decrease the cardiotoxic activities of Buserelin.Approved
BusulfanProscillaridin may decrease the cardiotoxic activities of Busulfan.Approved, Investigational
Buthionine SulfoximineProscillaridin may decrease the cardiotoxic activities of Buthionine Sulfoximine.Investigational
CabazitaxelProscillaridin may decrease the cardiotoxic activities of Cabazitaxel.Approved
CabergolineProscillaridin may decrease the cardiotoxic activities of Cabergoline.Approved
CabozantinibProscillaridin may decrease the cardiotoxic activities of Cabozantinib.Approved
CalcidiolCalcidiol may increase the arrhythmogenic activities of Proscillaridin.Approved, Nutraceutical
CalcipotriolProscillaridin may decrease the cardiotoxic activities of Calcipotriol.Approved
Calcium AcetateCalcium Acetate may increase the arrhythmogenic activities of Proscillaridin.Approved
Calcium CarbonateCalcium Carbonate may increase the arrhythmogenic activities of Proscillaridin.Approved
Calcium ChlorideCalcium Chloride may increase the arrhythmogenic activities of Proscillaridin.Approved
Calcium CitrateCalcium Citrate may increase the arrhythmogenic activities of Proscillaridin.Approved
Calcium glubionateCalcium glubionate may increase the arrhythmogenic activities of Proscillaridin.Approved
Calcium GluceptateCalcium Gluceptate may increase the arrhythmogenic activities of Proscillaridin.Approved
Calcium gluconateCalcium gluconate may increase the arrhythmogenic activities of Proscillaridin.Approved, Vet Approved
Calcium lactateCalcium lactate may increase the arrhythmogenic activities of Proscillaridin.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate may increase the arrhythmogenic activities of Proscillaridin.Experimental
Calcium laevulateCalcium laevulate may increase the arrhythmogenic activities of Proscillaridin.Experimental
Calcium pangamateCalcium pangamate may increase the arrhythmogenic activities of Proscillaridin.Experimental
Calcium PhosphateCalcium Phosphate may increase the arrhythmogenic activities of Proscillaridin.Approved
CamptothecinProscillaridin may decrease the cardiotoxic activities of Camptothecin.Experimental
CanertinibProscillaridin may decrease the cardiotoxic activities of Canertinib.Investigational
CapecitabineProscillaridin may decrease the cardiotoxic activities of Capecitabine.Approved, Investigational
CarbimazoleThe serum concentration of Proscillaridin can be increased when it is combined with Carbimazole.Approved, Investigational
CarbomycinThe serum concentration of Proscillaridin can be increased when it is combined with Carbomycin.Vet Approved
CarboplatinProscillaridin may decrease the cardiotoxic activities of Carboplatin.Approved
CarboquoneProscillaridin may decrease the cardiotoxic activities of Carboquone.Experimental
CarboxyamidotriazoleProscillaridin may decrease the cardiotoxic activities of Carboxyamidotriazole.Investigational
CarfilzomibProscillaridin may decrease the cardiotoxic activities of Carfilzomib.Approved
CarmofurProscillaridin may decrease the cardiotoxic activities of Carmofur.Withdrawn
CarmustineProscillaridin may decrease the cardiotoxic activities of Carmustine.Approved
CarteololCarteolol may increase the bradycardic activities of Proscillaridin.Approved
CarvedilolCarvedilol may increase the bradycardic activities of Proscillaridin.Approved, Investigational
CaseinCasein may increase the arrhythmogenic activities of Proscillaridin.Approved
CatumaxomabProscillaridin may decrease the cardiotoxic activities of Catumaxomab.Approved, Investigational
CediranibProscillaridin may decrease the cardiotoxic activities of Cediranib.Investigational
CeliprololCeliprolol may increase the bradycardic activities of Proscillaridin.Approved, Investigational
CeritinibProscillaridin may decrease the cardiotoxic activities of Ceritinib.Approved
CetuximabProscillaridin may decrease the cardiotoxic activities of Cetuximab.Approved
ChlorambucilProscillaridin may decrease the cardiotoxic activities of Chlorambucil.Approved
ChloroquineThe serum concentration of Proscillaridin can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Proscillaridin.Approved, Vet Approved
ChlorotrianiseneProscillaridin may decrease the cardiotoxic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Proscillaridin.Approved
CholesterolProscillaridin may decrease the cardiotoxic activities of Cholesterol.Experimental, Investigational
CholestyramineCholestyramine can cause a decrease in the absorption of Proscillaridin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinProscillaridin may decrease the cardiotoxic activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinProscillaridin may decrease the cardiotoxic activities of Ciprofloxacin.Approved, Investigational
CisatracuriumCisatracurium may increase the arrhythmogenic activities of Proscillaridin.Approved, Experimental
Cisatracurium besylateCisatracurium besylate may increase the arrhythmogenic activities of Proscillaridin.Approved
CisplatinProscillaridin may decrease the cardiotoxic activities of Cisplatin.Approved
CladribineProscillaridin may decrease the cardiotoxic activities of Cladribine.Approved, Investigational
ClarithromycinThe serum concentration of Proscillaridin can be increased when it is combined with Clarithromycin.Approved
ClofarabineProscillaridin may decrease the cardiotoxic activities of Clofarabine.Approved, Investigational
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Proscillaridin.Approved
CloranololCloranolol may increase the bradycardic activities of Proscillaridin.Experimental
CobimetinibProscillaridin may decrease the cardiotoxic activities of Cobimetinib.Approved
ColchicineProscillaridin may decrease the cardiotoxic activities of Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Proscillaridin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Proscillaridin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CombretastatinProscillaridin may decrease the cardiotoxic activities of Combretastatin.Investigational
CordycepinProscillaridin may decrease the cardiotoxic activities of Cordycepin.Investigational
Coumermycin A1Proscillaridin may decrease the cardiotoxic activities of Coumermycin A1.Experimental
CrenolanibProscillaridin may decrease the cardiotoxic activities of Crenolanib.Investigational
CrizotinibProscillaridin may decrease the cardiotoxic activities of Crizotinib.Approved
CurcuminProscillaridin may decrease the cardiotoxic activities of Curcumin.Investigational
CyclopenthiazideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Proscillaridin.Experimental
CyclophosphamideProscillaridin may decrease the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
Cyproterone acetateProscillaridin may decrease the cardiotoxic activities of Cyproterone acetate.Approved, Investigational
CytarabineProscillaridin may decrease the cardiotoxic activities of Cytarabine.Approved, Investigational
DabrafenibProscillaridin may decrease the cardiotoxic activities of Dabrafenib.Approved
DacarbazineProscillaridin may decrease the cardiotoxic activities of Dacarbazine.Approved, Investigational
DactinomycinProscillaridin may decrease the cardiotoxic activities of Dactinomycin.Approved
DaratumumabProscillaridin may decrease the cardiotoxic activities of Daratumumab.Approved
DasatinibProscillaridin may decrease the cardiotoxic activities of Dasatinib.Approved, Investigational
DaunorubicinProscillaridin may decrease the cardiotoxic activities of Daunorubicin.Approved
DecamethoniumDecamethonium may increase the arrhythmogenic activities of Proscillaridin.Approved
DecitabineProscillaridin may decrease the cardiotoxic activities of Decitabine.Approved, Investigational
DegarelixProscillaridin may decrease the cardiotoxic activities of Degarelix.Approved
DemecolcineProscillaridin may decrease the cardiotoxic activities of Demecolcine.Experimental
Denileukin diftitoxProscillaridin may decrease the cardiotoxic activities of Denileukin diftitox.Approved, Investigational
DeoxyspergualinProscillaridin may decrease the cardiotoxic activities of Deoxyspergualin.Investigational
DexamethasoneProscillaridin may decrease the cardiotoxic activities of Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneProscillaridin may decrease the cardiotoxic activities of Dexrazoxane.Approved, Withdrawn
DianhydrogalactitolProscillaridin may decrease the cardiotoxic activities of Dianhydrogalactitol.Investigational
DibekacinThe serum concentration of Proscillaridin can be decreased when it is combined with Dibekacin.Experimental
DidoxProscillaridin may decrease the cardiotoxic activities of Didox.Investigational
DienogestProscillaridin may decrease the cardiotoxic activities of Dienogest.Approved
diethylnorspermineProscillaridin may decrease the cardiotoxic activities of diethylnorspermine.Investigational
DiethylstilbestrolProscillaridin may decrease the cardiotoxic activities of Diethylstilbestrol.Approved, Investigational
DihydrostreptomycinThe serum concentration of Proscillaridin can be decreased when it is combined with Dihydrostreptomycin.Investigational, Vet Approved
DihydrotachysterolDihydrotachysterol may increase the arrhythmogenic activities of Proscillaridin.Approved
DiltiazemDiltiazem may increase the atrioventricular blocking (AV block) activities of Proscillaridin.Approved
DinutuximabProscillaridin may decrease the cardiotoxic activities of Dinutuximab.Approved
DocetaxelProscillaridin may decrease the cardiotoxic activities of Docetaxel.Approved, Investigational
Dolastatin 10Proscillaridin may decrease the cardiotoxic activities of Dolastatin 10.Investigational
Domoic AcidDomoic Acid may increase the arrhythmogenic activities of Proscillaridin.Experimental
Doxacurium chlorideDoxacurium chloride may increase the arrhythmogenic activities of Proscillaridin.Approved
DoxercalciferolDoxercalciferol may increase the arrhythmogenic activities of Proscillaridin.Approved
DoxifluridineProscillaridin may decrease the cardiotoxic activities of Doxifluridine.Investigational
DoxorubicinProscillaridin may decrease the cardiotoxic activities of Doxorubicin.Approved, Investigational
DuligotuzumabProscillaridin may decrease the cardiotoxic activities of Duligotuzumab.Investigational
EcabetProscillaridin may decrease the cardiotoxic activities of Ecabet.Approved, Investigational
EdrecolomabProscillaridin may decrease the cardiotoxic activities of Edrecolomab.Experimental, Investigational
EdrophoniumEdrophonium may increase the atrioventricular blocking (AV block) activities of Proscillaridin.Approved
EfaproxiralProscillaridin may decrease the cardiotoxic activities of Efaproxiral.Investigational
EfatutazoneProscillaridin may decrease the cardiotoxic activities of Efatutazone.Investigational
EflornithineProscillaridin may decrease the cardiotoxic activities of Eflornithine.Approved, Withdrawn
EG009Proscillaridin may decrease the cardiotoxic activities of EG009.Investigational
ElotuzumabProscillaridin may decrease the cardiotoxic activities of Elotuzumab.Approved
ElsamitrucinProscillaridin may decrease the cardiotoxic activities of Elsamitrucin.Investigational
EndostatinProscillaridin may decrease the cardiotoxic activities of Endostatin.Investigational
EnoxacinProscillaridin may decrease the cardiotoxic activities of Enoxacin.Approved, Investigational
EnrofloxacinProscillaridin may decrease the cardiotoxic activities of Enrofloxacin.Vet Approved
EntinostatProscillaridin may decrease the cardiotoxic activities of Entinostat.Investigational
EnzalutamideProscillaridin may decrease the cardiotoxic activities of Enzalutamide.Approved
EpanololEpanolol may increase the bradycardic activities of Proscillaridin.Experimental
Epigallocatechin GallateProscillaridin may decrease the cardiotoxic activities of Epigallocatechin Gallate.Investigational
EpirubicinProscillaridin may decrease the cardiotoxic activities of Epirubicin.Approved
EplerenoneThe therapeutic efficacy of Proscillaridin can be decreased when used in combination with Eplerenone.Approved
EpofolateProscillaridin may decrease the cardiotoxic activities of Epofolate.Investigational
ErgocalciferolErgocalciferol may increase the arrhythmogenic activities of Proscillaridin.Approved, Nutraceutical
EribulinProscillaridin may decrease the cardiotoxic activities of Eribulin.Approved, Investigational
ErlotinibProscillaridin may decrease the cardiotoxic activities of Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Proscillaridin can be increased when it is combined with Erythromycin.Approved, Vet Approved
EsmololEsmolol may increase the bradycardic activities of Proscillaridin.Approved
EstramustineProscillaridin may decrease the cardiotoxic activities of Estramustine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Proscillaridin.Approved
EtanidazoleProscillaridin may decrease the cardiotoxic activities of Etanidazole.Investigational
Ethiodized oilProscillaridin may decrease the cardiotoxic activities of Ethiodized oil.Approved
Ethyl carbamateProscillaridin may decrease the cardiotoxic activities of Ethyl carbamate.Withdrawn
EtoglucidProscillaridin may decrease the cardiotoxic activities of Etoglucid.Experimental
EtoposideProscillaridin may decrease the cardiotoxic activities of Etoposide.Approved
EverolimusProscillaridin may decrease the cardiotoxic activities of Everolimus.Approved
ExatecanProscillaridin may decrease the cardiotoxic activities of Exatecan.Investigational
ExemestaneProscillaridin may decrease the cardiotoxic activities of Exemestane.Approved, Investigational
exisulindProscillaridin may decrease the cardiotoxic activities of exisulind.Investigational
FenretinideProscillaridin may decrease the cardiotoxic activities of Fenretinide.Investigational
FiacitabineProscillaridin may decrease the cardiotoxic activities of Fiacitabine.Investigational
FleroxacinProscillaridin may decrease the cardiotoxic activities of Fleroxacin.Approved
FloxuridineProscillaridin may decrease the cardiotoxic activities of Floxuridine.Approved
FludarabineProscillaridin may decrease the cardiotoxic activities of Fludarabine.Approved
FlumequineProscillaridin may decrease the cardiotoxic activities of Flumequine.Withdrawn
FluorouracilProscillaridin may decrease the cardiotoxic activities of Fluorouracil.Approved
FlutamideProscillaridin may decrease the cardiotoxic activities of Flutamide.Approved
FormestaneProscillaridin may decrease the cardiotoxic activities of Formestane.Approved, Investigational, Withdrawn
FormycinProscillaridin may decrease the cardiotoxic activities of Formycin.Experimental
FosbretabulinProscillaridin may decrease the cardiotoxic activities of Fosbretabulin.Investigational
FotemustineProscillaridin may decrease the cardiotoxic activities of Fotemustine.Experimental, Investigational
FramycetinThe serum concentration of Proscillaridin can be decreased when it is combined with Framycetin.Approved
FulvestrantProscillaridin may decrease the cardiotoxic activities of Fulvestrant.Approved, Investigational
FumagillinProscillaridin may decrease the cardiotoxic activities of Fumagillin.Experimental
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Proscillaridin.Approved, Vet Approved
GallamineGallamine may increase the arrhythmogenic activities of Proscillaridin.Experimental
Gallamine TriethiodideGallamine Triethiodide may increase the arrhythmogenic activities of Proscillaridin.Approved
Gallium nitrateProscillaridin may decrease the cardiotoxic activities of Gallium nitrate.Approved, Investigational
GarenoxacinProscillaridin may decrease the cardiotoxic activities of Garenoxacin.Investigational
GatifloxacinProscillaridin may decrease the cardiotoxic activities of Gatifloxacin.Approved, Investigational
GefitinibProscillaridin may decrease the cardiotoxic activities of Gefitinib.Approved, Investigational
GeldanamycinProscillaridin may decrease the cardiotoxic activities of Geldanamycin.Experimental, Investigational
GemcitabineProscillaridin may decrease the cardiotoxic activities of Gemcitabine.Approved
GemifloxacinProscillaridin may decrease the cardiotoxic activities of Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinProscillaridin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.Approved
GeneticinThe serum concentration of Proscillaridin can be decreased when it is combined with Geneticin.Experimental
GenisteinProscillaridin may decrease the cardiotoxic activities of Genistein.Investigational
GentamicinThe serum concentration of Proscillaridin can be decreased when it is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of Proscillaridin can be decreased when it is combined with GENTAMICIN C1A.Experimental
Ginsenoside CProscillaridin may decrease the cardiotoxic activities of Ginsenoside C.Nutraceutical
GoserelinProscillaridin may decrease the cardiotoxic activities of Goserelin.Approved
GPX-150The serum concentration of Proscillaridin can be decreased when it is combined with GPX-150.Investigational
GrepafloxacinProscillaridin may decrease the cardiotoxic activities of Grepafloxacin.Investigational, Withdrawn
GS 0573Proscillaridin may decrease the cardiotoxic activities of GS 0573.Investigational
GusperimusProscillaridin may decrease the cardiotoxic activities of Gusperimus.Investigational
HadacidinProscillaridin may decrease the cardiotoxic activities of Hadacidin.Experimental
HalofuginoneProscillaridin may decrease the cardiotoxic activities of Halofuginone.Investigational, Vet Approved
HexestrolProscillaridin may decrease the cardiotoxic activities of Hexestrol.Withdrawn
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Proscillaridin.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Proscillaridin.Approved, Investigational
HydroxychloroquineThe serum concentration of Proscillaridin can be increased when it is combined with Hydroxychloroquine.Approved
Hydroxyprogesterone caproateProscillaridin may decrease the cardiotoxic activities of Hydroxyprogesterone caproate.Approved
HydroxyureaProscillaridin may decrease the cardiotoxic activities of Hydroxyurea.Approved
Hygromycin BThe serum concentration of Proscillaridin can be decreased when it is combined with Hygromycin B.Vet Approved
HypericinProscillaridin may decrease the cardiotoxic activities of Hypericin.Investigational
IbrutinibProscillaridin may decrease the cardiotoxic activities of Ibrutinib.Approved
IdarubicinProscillaridin may decrease the cardiotoxic activities of Idarubicin.Approved
IdelalisibProscillaridin may decrease the cardiotoxic activities of Idelalisib.Approved
IfosfamideProscillaridin may decrease the cardiotoxic activities of Ifosfamide.Approved
ImatinibProscillaridin may decrease the cardiotoxic activities of Imatinib.Approved
ImiquimodProscillaridin may decrease the cardiotoxic activities of Imiquimod.Approved, Investigational
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Proscillaridin.Approved
IndenololIndenolol may increase the bradycardic activities of Proscillaridin.Withdrawn
IndirubinProscillaridin may decrease the cardiotoxic activities of Indirubin.Investigational
Indole-3-carbinolProscillaridin may decrease the cardiotoxic activities of Indole-3-carbinol.Investigational
InfigratinibProscillaridin may decrease the cardiotoxic activities of Infigratinib.Investigational
IniparibProscillaridin may decrease the cardiotoxic activities of Iniparib.Experimental, Investigational
INNO-206The serum concentration of Proscillaridin can be decreased when it is combined with INNO-206.Investigational
Interferon Alfa-2b, RecombinantProscillaridin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Approved
Interferon beta-1aProscillaridin may decrease the cardiotoxic activities of Interferon beta-1a.Approved, Investigational
IobenguaneProscillaridin may decrease the cardiotoxic activities of Iobenguane.Approved, Investigational
IpilimumabProscillaridin may decrease the cardiotoxic activities of Ipilimumab.Approved
IrinotecanProscillaridin may decrease the cardiotoxic activities of Irinotecan.Approved, Investigational
IrofulvenProscillaridin may decrease the cardiotoxic activities of Irofulven.Investigational
IrsogladineProscillaridin may decrease the cardiotoxic activities of Irsogladine.Investigational
IsepamicinThe serum concentration of Proscillaridin can be decreased when it is combined with Isepamicin.Experimental
IsosorbideProscillaridin may decrease the cardiotoxic activities of Isosorbide.Approved, Investigational
ItraconazoleThe serum concentration of Proscillaridin can be increased when it is combined with Itraconazole.Approved, Investigational
IxabepiloneProscillaridin may decrease the cardiotoxic activities of Ixabepilone.Approved, Investigational
IxazomibProscillaridin may decrease the cardiotoxic activities of Ixazomib.Approved
JosamycinThe serum concentration of Proscillaridin can be increased when it is combined with Josamycin.Approved, Investigational
KanamycinThe serum concentration of Proscillaridin can be decreased when it is combined with Kanamycin.Approved, Investigational, Vet Approved
KaolinThe serum concentration of Proscillaridin can be decreased when it is combined with Kaolin.Approved
KitasamycinThe serum concentration of Proscillaridin can be increased when it is combined with Kitasamycin.Experimental
KOS-1584Proscillaridin may decrease the cardiotoxic activities of KOS-1584.Investigational
KRN-7000Proscillaridin may decrease the cardiotoxic activities of KRN-7000.Investigational
LabetalolLabetalol may increase the bradycardic activities of Proscillaridin.Approved
LandiololLandiolol may increase the bradycardic activities of Proscillaridin.Investigational
LanreotideProscillaridin may decrease the cardiotoxic activities of Lanreotide.Approved
LapatinibProscillaridin may decrease the cardiotoxic activities of Lapatinib.Approved, Investigational
LCL-161Proscillaridin may decrease the cardiotoxic activities of LCL-161.Investigational
LeflunomideProscillaridin may decrease the cardiotoxic activities of Leflunomide.Approved, Investigational
LenalidomideProscillaridin may decrease the cardiotoxic activities of Lenalidomide.Approved
LentinanProscillaridin may decrease the cardiotoxic activities of Lentinan.Experimental, Investigational
LenvatinibProscillaridin may decrease the cardiotoxic activities of Lenvatinib.Approved
LetrozoleProscillaridin may decrease the cardiotoxic activities of Letrozole.Approved, Investigational
LeuprolideProscillaridin may decrease the cardiotoxic activities of Leuprolide.Approved, Investigational
LevobunololLevobunolol may increase the bradycardic activities of Proscillaridin.Approved
LevofloxacinProscillaridin may decrease the cardiotoxic activities of Levofloxacin.Approved, Investigational
LiarozoleProscillaridin may decrease the cardiotoxic activities of Liarozole.Investigational
LicoriceThe risk or severity of adverse effects can be increased when Licorice is combined with Proscillaridin.Approved
LomefloxacinProscillaridin may decrease the cardiotoxic activities of Lomefloxacin.Approved, Investigational
LometrexolProscillaridin may decrease the cardiotoxic activities of Lometrexol.Investigational
LomustineProscillaridin may decrease the cardiotoxic activities of Lomustine.Approved
LonidamineProscillaridin may decrease the cardiotoxic activities of Lonidamine.Investigational
LurtotecanProscillaridin may decrease the cardiotoxic activities of Lurtotecan.Investigational
LycopeneProscillaridin may decrease the cardiotoxic activities of Lycopene.Approved
MafosfamideProscillaridin may decrease the cardiotoxic activities of Mafosfamide.Investigational
MannosulfanProscillaridin may decrease the cardiotoxic activities of Mannosulfan.Experimental
MasitinibProscillaridin may decrease the cardiotoxic activities of Masitinib.Investigational, Vet Approved
MasoprocolProscillaridin may decrease the cardiotoxic activities of Masoprocol.Approved, Investigational
MaxacalcitolProscillaridin may decrease the cardiotoxic activities of Maxacalcitol.Approved, Investigational
MebendazoleProscillaridin may decrease the cardiotoxic activities of Mebendazole.Approved, Vet Approved
MechlorethamineProscillaridin may decrease the cardiotoxic activities of Mechlorethamine.Approved
MedrogestoneProscillaridin may decrease the cardiotoxic activities of Medrogestone.Approved
Medroxyprogesterone acetateProscillaridin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateProscillaridin may decrease the cardiotoxic activities of Megestrol acetate.Approved, Vet Approved
MelphalanProscillaridin may decrease the cardiotoxic activities of Melphalan.Approved
MepindololMepindolol may increase the bradycardic activities of Proscillaridin.Experimental
MequinolProscillaridin may decrease the cardiotoxic activities of Mequinol.Approved
MercaptopurineProscillaridin may decrease the cardiotoxic activities of Mercaptopurine.Approved
MerestinibProscillaridin may decrease the cardiotoxic activities of Merestinib.Investigational
MesalazineThe serum concentration of Proscillaridin can be decreased when it is combined with Mesalazine.Approved
MethimazoleThe serum concentration of Proscillaridin can be increased when it is combined with Methimazole.Approved
MethotrexateProscillaridin may decrease the cardiotoxic activities of Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Proscillaridin.Approved
Methyl aminolevulinateProscillaridin may decrease the cardiotoxic activities of Methyl aminolevulinate.Approved
MethylprednisoloneProscillaridin may decrease the cardiotoxic activities of Methylprednisolone.Approved, Vet Approved
MethylselenocysteineProscillaridin may decrease the cardiotoxic activities of Methylselenocysteine.Investigational
MethyltestosteroneProscillaridin may decrease the cardiotoxic activities of Methyltestosterone.Approved
MethylthiouracilThe serum concentration of Proscillaridin can be increased when it is combined with Methylthiouracil.Experimental
MetipranololMetipranolol may increase the bradycardic activities of Proscillaridin.Approved
MetocurineMetocurine may increase the arrhythmogenic activities of Proscillaridin.Approved
Metocurine IodideMetocurine Iodide may increase the arrhythmogenic activities of Proscillaridin.Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Proscillaridin.Approved
MetoprineProscillaridin may decrease the cardiotoxic activities of Metoprine.Experimental
MetoprololMetoprolol may increase the bradycardic activities of Proscillaridin.Approved, Investigational
MetrizamideThe serum concentration of Proscillaridin can be decreased when it is combined with Metrizamide.Approved
MicronomicinThe serum concentration of Proscillaridin can be decreased when it is combined with Micronomicin.Experimental
MidodrineProscillaridin may increase the bradycardic activities of Midodrine.Approved
MidostaurinProscillaridin may decrease the cardiotoxic activities of Midostaurin.Approved
MiltefosineProscillaridin may decrease the cardiotoxic activities of Miltefosine.Approved
MisonidazoleProscillaridin may decrease the cardiotoxic activities of Misonidazole.Investigational
MitobronitolProscillaridin may decrease the cardiotoxic activities of Mitobronitol.Experimental
MitoguazoneProscillaridin may decrease the cardiotoxic activities of Mitoguazone.Investigational
MitolactolProscillaridin may decrease the cardiotoxic activities of Mitolactol.Investigational
MitomycinProscillaridin may decrease the cardiotoxic activities of Mitomycin.Approved
MitotaneProscillaridin may decrease the cardiotoxic activities of Mitotane.Approved
MitoxantroneProscillaridin may decrease the cardiotoxic activities of Mitoxantrone.Approved, Investigational
MivacuriumMivacurium may increase the arrhythmogenic activities of Proscillaridin.Approved
MizoribineProscillaridin may decrease the cardiotoxic activities of Mizoribine.Investigational
MLN576Proscillaridin may decrease the cardiotoxic activities of MLN576.Investigational
MolgramostimProscillaridin may decrease the cardiotoxic activities of Molgramostim.Investigational
motexafin gadoliniumProscillaridin may decrease the cardiotoxic activities of motexafin gadolinium.Investigational
MoxifloxacinProscillaridin may decrease the cardiotoxic activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilProscillaridin may decrease the cardiotoxic activities of Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidProscillaridin may decrease the cardiotoxic activities of Mycophenolic acid.Approved
NadifloxacinProscillaridin may decrease the cardiotoxic activities of Nadifloxacin.Investigational
NadololNadolol may increase the bradycardic activities of Proscillaridin.Approved
Nalidixic AcidProscillaridin may decrease the cardiotoxic activities of Nalidixic Acid.Approved, Investigational
NamitecanProscillaridin may decrease the cardiotoxic activities of Namitecan.Investigational
NavitoclaxProscillaridin may decrease the cardiotoxic activities of Navitoclax.Investigational
NeamineThe serum concentration of Proscillaridin can be decreased when it is combined with Neamine.Experimental
NebivololNebivolol may increase the bradycardic activities of Proscillaridin.Approved, Investigational
NebularineProscillaridin may decrease the cardiotoxic activities of Nebularine.Experimental
NecitumumabProscillaridin may decrease the cardiotoxic activities of Necitumumab.Approved
NedaplatinProscillaridin may decrease the cardiotoxic activities of Nedaplatin.Approved, Investigational
NelarabineProscillaridin may decrease the cardiotoxic activities of Nelarabine.Approved, Investigational
NeomycinThe serum concentration of Proscillaridin can be decreased when it is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinNeosaxitoxin may increase the arrhythmogenic activities of Proscillaridin.Investigational
NetilmicinThe serum concentration of Proscillaridin can be decreased when it is combined with Netilmicin.Approved, Investigational
NiguldipineProscillaridin may decrease the cardiotoxic activities of Niguldipine.Experimental
NilotinibProscillaridin may decrease the cardiotoxic activities of Nilotinib.Approved, Investigational
NilutamideProscillaridin may decrease the cardiotoxic activities of Nilutamide.Approved
NimustineProscillaridin may decrease the cardiotoxic activities of Nimustine.Investigational
NintedanibProscillaridin may decrease the cardiotoxic activities of Nintedanib.Approved
NiraparibProscillaridin may decrease the cardiotoxic activities of Niraparib.Approved, Investigational
NivolumabProscillaridin may decrease the cardiotoxic activities of Nivolumab.Approved
nocodazoleProscillaridin may decrease the cardiotoxic activities of nocodazole.Experimental
NolatrexedProscillaridin may decrease the cardiotoxic activities of Nolatrexed.Investigational
NorfloxacinProscillaridin may decrease the cardiotoxic activities of Norfloxacin.Approved
ObinutuzumabProscillaridin may decrease the cardiotoxic activities of Obinutuzumab.Approved
OblimersenProscillaridin may decrease the cardiotoxic activities of Oblimersen.Experimental, Investigational
OBP-801Proscillaridin may decrease the cardiotoxic activities of OBP-801.Investigational
OctreotideProscillaridin may decrease the cardiotoxic activities of Octreotide.Approved, Investigational
OfatumumabProscillaridin may decrease the cardiotoxic activities of Ofatumumab.Approved
OfloxacinProscillaridin may decrease the cardiotoxic activities of Ofloxacin.Approved
OglufanideProscillaridin may decrease the cardiotoxic activities of Oglufanide.Investigational
OlaparibProscillaridin may decrease the cardiotoxic activities of Olaparib.Approved
OleandomycinThe serum concentration of Proscillaridin can be increased when it is combined with Oleandomycin.Vet Approved
OlsalazineThe serum concentration of Proscillaridin can be decreased when it is combined with Olsalazine.Approved
OltiprazProscillaridin may decrease the cardiotoxic activities of Oltipraz.Investigational
Omacetaxine mepesuccinateProscillaridin may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.Approved
OnapristoneProscillaridin may decrease the cardiotoxic activities of Onapristone.Investigational
OprelvekinProscillaridin may decrease the cardiotoxic activities of Oprelvekin.Approved, Investigational
OsimertinibProscillaridin may decrease the cardiotoxic activities of Osimertinib.Approved
OxaliplatinProscillaridin may decrease the cardiotoxic activities of Oxaliplatin.Approved, Investigational
Oxolinic acidProscillaridin may decrease the cardiotoxic activities of Oxolinic acid.Experimental
OxprenololOxprenolol may increase the bradycardic activities of Proscillaridin.Approved
PaclitaxelProscillaridin may decrease the cardiotoxic activities of Paclitaxel.Approved, Vet Approved
Paclitaxel poliglumexProscillaridin may decrease the cardiotoxic activities of Paclitaxel poliglumex.Experimental, Investigational
PalbociclibProscillaridin may decrease the cardiotoxic activities of Palbociclib.Approved
PalifosfamideProscillaridin may decrease the cardiotoxic activities of Palifosfamide.Investigational
PamidronateProscillaridin may decrease the cardiotoxic activities of Pamidronate.Approved
PancuroniumPancuronium may increase the arrhythmogenic activities of Proscillaridin.Approved
PanitumumabProscillaridin may decrease the cardiotoxic activities of Panitumumab.Approved, Investigational
PanobinostatProscillaridin may decrease the cardiotoxic activities of Panobinostat.Approved, Investigational
Parathyroid hormoneThe risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Proscillaridin.Approved, Investigational
ParicalcitolParicalcitol may increase the arrhythmogenic activities of Proscillaridin.Approved, Investigational
ParomomycinThe serum concentration of Proscillaridin can be decreased when it is combined with Paromomycin.Approved, Investigational
PatupiloneProscillaridin may decrease the cardiotoxic activities of Patupilone.Experimental, Investigational
PazopanibProscillaridin may decrease the cardiotoxic activities of Pazopanib.Approved
PazufloxacinProscillaridin may decrease the cardiotoxic activities of Pazufloxacin.Investigational
PefloxacinProscillaridin may decrease the cardiotoxic activities of Pefloxacin.Approved
PegaspargaseProscillaridin may decrease the cardiotoxic activities of Pegaspargase.Approved, Investigational
PembrolizumabProscillaridin may decrease the cardiotoxic activities of Pembrolizumab.Approved
PemetrexedProscillaridin may decrease the cardiotoxic activities of Pemetrexed.Approved, Investigational
PenbutololPenbutolol may increase the bradycardic activities of Proscillaridin.Approved, Investigational
PenclomedineProscillaridin may decrease the cardiotoxic activities of Penclomedine.Investigational
PentostatinProscillaridin may decrease the cardiotoxic activities of Pentostatin.Approved, Investigational
PertuzumabProscillaridin may decrease the cardiotoxic activities of Pertuzumab.Approved
Phenethyl IsothiocyanateProscillaridin may decrease the cardiotoxic activities of Phenethyl Isothiocyanate.Investigational
Phenylacetic acidProscillaridin may decrease the cardiotoxic activities of Phenylacetic acid.Approved
Phenylbutyric acidProscillaridin may decrease the cardiotoxic activities of Phenylbutyric acid.Approved, Investigational
PindololPindolol may increase the bradycardic activities of Proscillaridin.Approved
PinometostatProscillaridin may decrease the cardiotoxic activities of Pinometostat.Investigational
PipecuroniumPipecuronium may increase the arrhythmogenic activities of Proscillaridin.Approved
PipobromanProscillaridin may decrease the cardiotoxic activities of Pipobroman.Approved
PirarubicinProscillaridin may decrease the cardiotoxic activities of Pirarubicin.Investigational
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Proscillaridin.Experimental
PirfenidoneProscillaridin may decrease the cardiotoxic activities of Pirfenidone.Approved, Investigational
PirlindoleProscillaridin may decrease the cardiotoxic activities of Pirlindole.Approved
PixantroneProscillaridin may decrease the cardiotoxic activities of Pixantrone.Approved, Investigational
Platelet Activating FactorPlatelet Activating Factor may increase the bradycardic activities of Proscillaridin.Experimental
PlazomicinThe serum concentration of Proscillaridin can be decreased when it is combined with Plazomicin.Investigational
PlevitrexedProscillaridin may decrease the cardiotoxic activities of Plevitrexed.Investigational
PlicamycinProscillaridin may decrease the cardiotoxic activities of Plicamycin.Approved, Investigational, Withdrawn
PodofiloxProscillaridin may decrease the cardiotoxic activities of Podofilox.Approved
PodophyllinProscillaridin may decrease the cardiotoxic activities of Podophyllin.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Proscillaridin.Approved
PomalidomideProscillaridin may decrease the cardiotoxic activities of Pomalidomide.Approved
PonatinibProscillaridin may decrease the cardiotoxic activities of Ponatinib.Approved
Porfimer sodiumProscillaridin may decrease the cardiotoxic activities of Porfimer sodium.Approved, Investigational
porfiromycinProscillaridin may decrease the cardiotoxic activities of porfiromycin.Investigational
Potassium IodideThe serum concentration of Proscillaridin can be increased when it is combined with Potassium Iodide.Approved
PractololPractolol may increase the bradycardic activities of Proscillaridin.Approved
PralatrexateProscillaridin may decrease the cardiotoxic activities of Pralatrexate.Approved
PrednimustineProscillaridin may decrease the cardiotoxic activities of Prednimustine.Investigational
PrednisoloneProscillaridin may decrease the cardiotoxic activities of Prednisolone.Approved, Vet Approved
PrednisoneProscillaridin may decrease the cardiotoxic activities of Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of Proscillaridin can be increased when it is combined with Primaquine.Approved
ProcarbazineProscillaridin may decrease the cardiotoxic activities of Procarbazine.Approved
PropafenoneThe serum concentration of Proscillaridin can be increased when it is combined with Propafenone.Approved
PropranololPropranolol may increase the bradycardic activities of Proscillaridin.Approved, Investigational
PropylthiouracilThe serum concentration of Proscillaridin can be increased when it is combined with Propylthiouracil.Approved
PrulifloxacinProscillaridin may decrease the cardiotoxic activities of Prulifloxacin.Investigational
PuromycinProscillaridin may decrease the cardiotoxic activities of Puromycin.Experimental
PyrantelPyrantel may increase the arrhythmogenic activities of Proscillaridin.Approved, Vet Approved
PyrazoloacridineProscillaridin may decrease the cardiotoxic activities of Pyrazoloacridine.Investigational
QuinacrineProscillaridin may decrease the cardiotoxic activities of Quinacrine.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Proscillaridin.Approved
QuinidineThe serum concentration of Proscillaridin can be increased when it is combined with Quinidine.Approved
RabusertibProscillaridin may decrease the cardiotoxic activities of Rabusertib.Investigational
Radium Ra 223 DichlorideProscillaridin may decrease the cardiotoxic activities of Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedProscillaridin may decrease the cardiotoxic activities of Raltitrexed.Approved, Investigational
RamucirumabProscillaridin may decrease the cardiotoxic activities of Ramucirumab.Approved, Investigational
RanibizumabProscillaridin may decrease the cardiotoxic activities of Ranibizumab.Approved
RanimustineProscillaridin may decrease the cardiotoxic activities of Ranimustine.Experimental
RanpirnaseProscillaridin may decrease the cardiotoxic activities of Ranpirnase.Investigational
RapacuroniumRapacuronium may increase the arrhythmogenic activities of Proscillaridin.Withdrawn
RegorafenibProscillaridin may decrease the cardiotoxic activities of Regorafenib.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Proscillaridin.Approved, Investigational
ResveratrolProscillaridin may decrease the cardiotoxic activities of Resveratrol.Approved, Experimental, Investigational
Rhodamine 6GProscillaridin may decrease the cardiotoxic activities of Rhodamine 6G.Experimental
RibostamycinThe serum concentration of Proscillaridin can be decreased when it is combined with Ribostamycin.Approved, Investigational
RidaforolimusProscillaridin may decrease the cardiotoxic activities of Ridaforolimus.Investigational
RituximabProscillaridin may decrease the cardiotoxic activities of Rituximab.Approved
RocuroniumRocuronium may increase the arrhythmogenic activities of Proscillaridin.Approved
RomidepsinProscillaridin may decrease the cardiotoxic activities of Romidepsin.Approved, Investigational
RoquinimexProscillaridin may decrease the cardiotoxic activities of Roquinimex.Investigational
RubitecanProscillaridin may decrease the cardiotoxic activities of Rubitecan.Investigational
RucaparibProscillaridin may decrease the cardiotoxic activities of Rucaparib.Approved, Investigational
RufloxacinProscillaridin may decrease the cardiotoxic activities of Rufloxacin.Experimental
RuxolitinibProscillaridin may decrease the cardiotoxic activities of Ruxolitinib.Approved
SabarubicinThe serum concentration of Proscillaridin can be decreased when it is combined with Sabarubicin.Investigational
SalirasibProscillaridin may decrease the cardiotoxic activities of Salirasib.Investigational
SaracatinibProscillaridin may decrease the cardiotoxic activities of Saracatinib.Investigational
SatraplatinProscillaridin may decrease the cardiotoxic activities of Satraplatin.Investigational
SeliciclibProscillaridin may decrease the cardiotoxic activities of Seliciclib.Investigational
SemaxanibProscillaridin may decrease the cardiotoxic activities of Semaxanib.Investigational
SemustineProscillaridin may decrease the cardiotoxic activities of Semustine.Experimental, Investigational
SeocalcitolProscillaridin may decrease the cardiotoxic activities of Seocalcitol.Experimental, Investigational
SiltuximabProscillaridin may decrease the cardiotoxic activities of Siltuximab.Approved
SirolimusProscillaridin may decrease the cardiotoxic activities of Sirolimus.Approved, Investigational
SisomicinThe serum concentration of Proscillaridin can be decreased when it is combined with Sisomicin.Investigational
SitafloxacinProscillaridin may decrease the cardiotoxic activities of Sitafloxacin.Experimental, Investigational
SizofiranProscillaridin may decrease the cardiotoxic activities of Sizofiran.Investigational
SoblidotinProscillaridin may decrease the cardiotoxic activities of Soblidotin.Investigational
SolithromycinThe serum concentration of Proscillaridin can be increased when it is combined with Solithromycin.Investigational
SonidegibProscillaridin may decrease the cardiotoxic activities of Sonidegib.Approved, Investigational
SorafenibProscillaridin may decrease the cardiotoxic activities of Sorafenib.Approved, Investigational
SotalolSotalol may increase the bradycardic activities of Proscillaridin.Approved
SP1049CThe serum concentration of Proscillaridin can be decreased when it is combined with SP1049C.Investigational
SparfloxacinProscillaridin may decrease the cardiotoxic activities of Sparfloxacin.Approved, Investigational
Sparfosic acidProscillaridin may decrease the cardiotoxic activities of Sparfosic acid.Experimental
SparsomycinProscillaridin may decrease the cardiotoxic activities of Sparsomycin.Experimental
SpectinomycinThe serum concentration of Proscillaridin can be decreased when it is combined with Spectinomycin.Approved, Investigational, Vet Approved
SpiramycinThe serum concentration of Proscillaridin can be increased when it is combined with Spiramycin.Approved
SpironolactoneThe therapeutic efficacy of Proscillaridin can be decreased when used in combination with Spironolactone.Approved
squalamineProscillaridin may decrease the cardiotoxic activities of squalamine.Investigational
SRT501Proscillaridin may decrease the cardiotoxic activities of SRT501.Investigational
StreptomycinThe serum concentration of Proscillaridin can be decreased when it is combined with Streptomycin.Approved, Vet Approved
StreptozocinProscillaridin may decrease the cardiotoxic activities of Streptozocin.Approved
SuccinylcholineSuccinylcholine may increase the arrhythmogenic activities of Proscillaridin.Approved
SulforaphaneProscillaridin may decrease the cardiotoxic activities of Sulforaphane.Investigational
SulindacProscillaridin may decrease the cardiotoxic activities of Sulindac.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Proscillaridin.Approved, Investigational
SunitinibProscillaridin may decrease the cardiotoxic activities of Sunitinib.Approved, Investigational
SuraminProscillaridin may decrease the cardiotoxic activities of Suramin.Approved, Investigational
TalaporfinProscillaridin may decrease the cardiotoxic activities of Talaporfin.Investigational
TalazoparibProscillaridin may decrease the cardiotoxic activities of Talazoparib.Investigational
TalinololTalinolol may increase the bradycardic activities of Proscillaridin.Investigational
TamoxifenProscillaridin may decrease the cardiotoxic activities of Tamoxifen.Approved
TaselisibProscillaridin may decrease the cardiotoxic activities of Taselisib.Investigational
TaurolidineProscillaridin may decrease the cardiotoxic activities of Taurolidine.Investigational
TegafurProscillaridin may decrease the cardiotoxic activities of Tegafur.Approved
TelithromycinThe serum concentration of Proscillaridin can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Proscillaridin can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinProscillaridin may decrease the cardiotoxic activities of Temafloxacin.Withdrawn
TemoporfinProscillaridin may decrease the cardiotoxic activities of Temoporfin.Approved, Investigational
TemozolomideProscillaridin may decrease the cardiotoxic activities of Temozolomide.Approved, Investigational
TemsirolimusProscillaridin may decrease the cardiotoxic activities of Temsirolimus.Approved
TeniposideProscillaridin may decrease the cardiotoxic activities of Teniposide.Approved
TertatololTertatolol may increase the bradycardic activities of Proscillaridin.Experimental
TestolactoneProscillaridin may decrease the cardiotoxic activities of Testolactone.Approved, Investigational
TezacitabineProscillaridin may decrease the cardiotoxic activities of Tezacitabine.Investigational
ThalidomideProscillaridin may decrease the cardiotoxic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiotepaProscillaridin may decrease the cardiotoxic activities of Thiotepa.Approved
ThymalfasinProscillaridin may decrease the cardiotoxic activities of Thymalfasin.Approved, Investigational
TiazofurineProscillaridin may decrease the cardiotoxic activities of Tiazofurine.Experimental
TiboloneProscillaridin may decrease the cardiotoxic activities of Tibolone.Approved, Investigational
TimololTimolol may increase the bradycardic activities of Proscillaridin.Approved
TioguanineProscillaridin may decrease the cardiotoxic activities of Tioguanine.Approved
Tiomolibdate ionProscillaridin may decrease the cardiotoxic activities of Tiomolibdate ion.Investigational
TipifarnibProscillaridin may decrease the cardiotoxic activities of Tipifarnib.Investigational
TirapazamineProscillaridin may decrease the cardiotoxic activities of Tirapazamine.Investigational
TivozanibProscillaridin may decrease the cardiotoxic activities of Tivozanib.Investigational
TobramycinThe serum concentration of Proscillaridin can be decreased when it is combined with Tobramycin.Approved, Investigational
TolevamerThe risk or severity of adverse effects can be increased when Tolevamer is combined with Proscillaridin.Approved
TopotecanProscillaridin may decrease the cardiotoxic activities of Topotecan.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Proscillaridin.Approved
ToremifeneProscillaridin may decrease the cardiotoxic activities of Toremifene.Approved, Investigational
TositumomabProscillaridin may decrease the cardiotoxic activities of Tositumomab.Approved, Investigational
ToyocamycinProscillaridin may decrease the cardiotoxic activities of Toyocamycin.Experimental
TrabectedinProscillaridin may decrease the cardiotoxic activities of Trabectedin.Approved, Investigational
TrametinibProscillaridin may decrease the cardiotoxic activities of Trametinib.Approved
TrastuzumabProscillaridin may decrease the cardiotoxic activities of Trastuzumab.Approved, Investigational
Trastuzumab emtansineProscillaridin may decrease the cardiotoxic activities of Trastuzumab emtansine.Approved
TrebananibProscillaridin may decrease the cardiotoxic activities of Trebananib.Investigational
TremelimumabProscillaridin may decrease the cardiotoxic activities of Tremelimumab.Investigational
TreosulfanProscillaridin may decrease the cardiotoxic activities of Treosulfan.Investigational
TretazicarProscillaridin may decrease the cardiotoxic activities of Tretazicar.Investigational
TretinoinProscillaridin may decrease the cardiotoxic activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe therapeutic efficacy of Proscillaridin can be decreased when used in combination with Triamterene.Approved
TriaziquoneProscillaridin may decrease the cardiotoxic activities of Triaziquone.Experimental
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Proscillaridin.Approved, Vet Approved
TrifluridineProscillaridin may decrease the cardiotoxic activities of Trifluridine.Approved
TrilostaneProscillaridin may decrease the cardiotoxic activities of Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimetrexateProscillaridin may decrease the cardiotoxic activities of Trimetrexate.Approved, Investigational
TriptolideProscillaridin may decrease the cardiotoxic activities of Triptolide.Investigational
TriptorelinProscillaridin may decrease the cardiotoxic activities of Triptorelin.Approved, Vet Approved
TrofosfamideProscillaridin may decrease the cardiotoxic activities of Trofosfamide.Investigational
TrovafloxacinProscillaridin may decrease the cardiotoxic activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxacitabineProscillaridin may decrease the cardiotoxic activities of Troxacitabine.Investigational
TubercidinProscillaridin may decrease the cardiotoxic activities of Tubercidin.Experimental
TubocurarineTubocurarine may increase the arrhythmogenic activities of Proscillaridin.Approved
TylosinThe serum concentration of Proscillaridin can be increased when it is combined with Tylosin.Vet Approved
UbenimexProscillaridin may decrease the cardiotoxic activities of Ubenimex.Experimental, Investigational
Uracil mustardProscillaridin may decrease the cardiotoxic activities of Uracil mustard.Approved
VadimezanProscillaridin may decrease the cardiotoxic activities of Vadimezan.Investigational
ValrubicinProscillaridin may decrease the cardiotoxic activities of Valrubicin.Approved
VandetanibProscillaridin may decrease the cardiotoxic activities of Vandetanib.Approved
VapreotideProscillaridin may decrease the cardiotoxic activities of Vapreotide.Approved, Investigational
VecuroniumVecuronium may increase the arrhythmogenic activities of Proscillaridin.Approved
VeliparibProscillaridin may decrease the cardiotoxic activities of Veliparib.Investigational
VemurafenibProscillaridin may decrease the cardiotoxic activities of Vemurafenib.Approved
VenetoclaxProscillaridin may decrease the cardiotoxic activities of Venetoclax.Approved
VerapamilVerapamil may increase the atrioventricular blocking (AV block) activities of Proscillaridin.Approved
VerteporfinProscillaridin may decrease the cardiotoxic activities of Verteporfin.Approved, Investigational
VesnarinoneProscillaridin may decrease the cardiotoxic activities of Vesnarinone.Investigational
VinblastineProscillaridin may decrease the cardiotoxic activities of Vinblastine.Approved
VincristineProscillaridin may decrease the cardiotoxic activities of Vincristine.Approved, Investigational
VindesineProscillaridin may decrease the cardiotoxic activities of Vindesine.Approved, Investigational
VinflunineProscillaridin may decrease the cardiotoxic activities of Vinflunine.Approved
VinorelbineProscillaridin may decrease the cardiotoxic activities of Vinorelbine.Approved, Investigational
VintafolideProscillaridin may decrease the cardiotoxic activities of Vintafolide.Investigational
VismodegibProscillaridin may decrease the cardiotoxic activities of Vismodegib.Approved
Vitamin AProscillaridin may decrease the cardiotoxic activities of Vitamin A.Approved, Nutraceutical, Vet Approved
VorinostatProscillaridin may decrease the cardiotoxic activities of Vorinostat.Approved, Investigational
VorozoleProscillaridin may decrease the cardiotoxic activities of Vorozole.Experimental
Zoptarelin doxorubicinThe serum concentration of Proscillaridin can be decreased when it is combined with Zoptarelin doxorubicin.Investigational
ZorubicinProscillaridin may decrease the cardiotoxic activities of Zorubicin.Experimental
Zuretinol acetateProscillaridin may decrease the cardiotoxic activities of Zuretinol acetate.Investigational
Food Interactions
Not Available

References

General References
  1. Bielawski K, Winnicka K, Bielawska A: Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol Pharm Bull. 2006 Jul;29(7):1493-7. [PubMed:16819197]
  2. Denicolai E, Baeza-Kallee N, Tchoghandjian A, Carre M, Colin C, Jiglaire CJ, Mercurio S, Beclin C, Figarella-Branger D: Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo. Oncotarget. 2014 Nov 15;5(21):10934-48. [PubMed:25400117]
External Links
PubChem Compound
5284613
PubChem Substance
347829292
ChemSpider
4447658
ChEBI
32065
ChEMBL
CHEMBL600325
ATC Codes
C01AB51 — Proscillaridin, combinationsC01AB01 — Proscillaridin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0427 mg/mLALOGPS
logP2.37ALOGPS
logP2.3ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)12.22ChemAxon
pKa (Strongest Basic)0.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area125.68 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity140.05 m3·mol-1ChemAxon
Polarizability58.26 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as bufanolides and derivatives. These are steroid lactones containing a pyran-2-one moiety linked to the C17 atom of a cyclopenta[a]phenanthrene derivative.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid lactones
Direct Parent
Bufanolides and derivatives
Alternative Parents
Steroidal glycosides / 14-hydroxysteroids / Delta-4-steroids / Hexoses / O-glycosyl compounds / Pyranones and derivatives / Oxanes / Tertiary alcohols / Heteroaromatic compounds / Lactones
show 7 more
Substituents
Bufanolide-skeleton / Steroidal glycoside / 14-hydroxysteroid / Hydroxysteroid / Delta-4-steroid / Hexose monosaccharide / Glycosyl compound / O-glycosyl compound / Pyranone / Pyran
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:39 / Updated on December 01, 2017 16:39